Zanthoxylum Species: A Review of Traditional Uses, Phytochemistry and Pharmacology in Relation to Cancer, Infectious Diseases and Sickle Cell Anemia

Innocent Uzochukwu Okagu1, Joseph Chinedum Ndefo2*, Emmanuel Chigozie Aham1,3 and Chibuike. C. Udenigwe4*

1Department of Biochemistry, University of Nigeria, Nsukka, Nigeria, 2Department of Science Laboratory Technology, University of Nigeria, Nsukka, Nigeria, 3Natural Science Unit, School of General Studies, University of Nigeria, Nsukka, Nigeria, 4School of Nutrition Sciences, University of Ottawa, Ottawa, ON, Canada

The health benefits and toxicity of plant products are largely dependent on their secondary metabolite contents. These compounds are biosynthesized by plants as protection mechanisms against environmental factors and infectious agents. This review discusses the traditional uses, phytochemical constituents and health benefits of plant species in genus Zanthoxylum with a focus on cancer, microbial and parasitic infections, and sickle cell disease as reported in articles published from 1970 to 2021 in peer-reviewed journals and indexed in major scientific databases. Generally, Z. species are widely distributed in Asia, America and Africa, where they are used as food and for disease treatment. Several compounds belonging to alkaloids, flavonoids, terpenoids, and lignans, among others have been isolated from Z. species. This review discusses the biological activities reported for the plant species and their phytochemicals, including anticancer, antibacterial, antifungal, antiviral, anti-trypanosomal, antimalarial and anti-sickling properties. The safety profiles and suggestions for conservation of the Z. species were also discussed. Taken together, this review demonstrates that Z. species are rich in a wide range of bioactive phytochemicals with multiple health benefits, but more research is needed towards their practical application in the development of functional foods, nutraceuticals and lead compounds for new drugs.

Keywords: Zanthoxylum, Ethnobotany, health benefits, phytochemicals, functional foods, Nutraceuticals

INTRODUCTION

Humans have continually depended on plants for food and medicine. Plants produce secondary metabolites in response to infective agents and environmental factors. Consequently, efforts have been made to isolate, characterize and investigate the beneficial effects of plant-derived secondary metabolites on human health. Notably, several bioactive compounds from plants have provided inspirations for the synthesis of chemical drugs, such as artesunates from artemisinins and quinolone antimalarials from quinine (Karunamoorthi et al., 2013; Lifongo et al., 2014; Pawar 2014; Numonov et al., 2019). Natural product chemists often rely on traditional knowledge on plants with medicinal potentials...
to produce crude extracts with biological activities. This process is followed by downstream processing to isolate the bioactive compounds, and structural characterization to identify them. In some cases, chemical modifications of the phytochemicals are used to produce more clinically effective and safer entities.

**Zanthoxylum** species, also known as **Fagara** species, have a long history of use as sources of food and drug by locals in different parts of Asia, America and Africa. In traditional medicine, many of the plant species are used in treating sickle cell anemia, trypanosomiasis, malaria and microbial infections, including tuberculosis and enteritis, with *Z. zanthoxyloides* Lam being the most reported species for these applications (Erichsen-Brown 1979; Burkill 1985). For example, fruits of *Z. lepreuri* Guill. and Perr. and *Z. zanthoxyloides* Lam are used in managing fever, malaria, tumors and sickle cell anemia (Tamdem 2019) while the stem bark, leaves, and roots are applied to suppress pain, and to treat arthritis, leprosy, stomachache and venereal diseases in Cameroon (Burkill 1998; Ngoumfo et al., 2010). Furthermore, different parts of *Z. lepreuri* are used to treat or manage tuberculosis, malaria, human immunodeficiency virus (HIV) and several types of bacterial infection in Uganda and other parts of Africa (Lamorde et al., 2010; Tabuti et al., 2010; Bunalema et al., 2014). In China and other parts of Eastern Asia, *Z. bungeanum* Maxim. (Syn. *Z. piperitum* Benn.) is widely used as a food condiment because of its perceived health benefits (Hwang et al. 2008) and as cosmetics for maintaining skin quality (Hwang et al., 2020). In Chinese medicine, *Z. bungeanum* is used as spices and for treating infection and bone diseases (Lee and Lim 2008; Kim et al., 2017). The leaves, fruits and barks are used in treating bacterial and fungal infections, as spices, and for food preservation in Japan (Hatano et al., 2004). Similarly, different parts of *Z. schinifolium* Siebold and Zucc. are used as food condiments and for treating stomach pain, diarrhea, jaundice, and cold in Eastern Asia (Cui et al., 2009). Furthermore, herbal preparation from different parts of *Z. americanum* Mill. is traditionally used for treating tumors, fungal skin infections, respiratory, urinary, genital and gastrointestinal (GIT) diseases by herbal healers in Canada and United States (Moerman 1998). In Kanayat Dayak Community, West Kalimantan, Indonesia, the stem and root of *Z. bungeanum* are consumed raw or after boiling in water to prevent alcohol intoxication and treat respiratory diseases (Sepsamli and Prihastanti 2019). Other traditional and ethnobotanical uses of *Z.* species have been discussed elsewhere (Patiño et al., 2012; Adewole 2020; Lu et al., 2020a; Obakiro et al., 2020; Okagu et al., 2021). The objectives of this review are to discuss (1) the potential of *Z.* species as sources of bioactive phytochemicals that can be applied in the management and treatment of cancer, microbial and parasitic infections, and sickle cell disease; (2) chemical constituents involved in these biological activities; and (3) safety issues and suggestions for conservation of the plant species.

**LITERATURE SEARCH STRATEGY AND CRITERIA FOR SELECTION OF ARTICLES**

This study used a strategy similar to that reported by Nigussie et al. (2021). From repositories and search engines (PubMed, ScienceDirect, and Google Scholar), information related to the health benefits of *Z.* species, with emphasis on anticancer, antitrypanosomal, antimicrobial, antiviral, amimalarial and anti-sickling properties, in peer-reviewed journals and ethnobotanical surveys published from 1970-July 3, 2021 were retrieved. The titles and abstracts of the studies were scanned using the inclusion criteria for this study. The search terms included cytotoxicity, anticancer, antimicrobial, antibacterial, anti-mycobacterial, antimalarial, antiviral, larvicidal, trypanocidal, anti-sickling and antiproliferative effect of *Zanthoxylum* species, *Fagara* species, and medicinal plants. In some cases, articles citing older papers and references of recent papers were used to obtain additional articles of interest. Studies reporting the biological activities of interest on different parts of *Z.* species including seeds, fruits, stem/stem bark, fruits, and root/root bark were included. Biological activities of crude extracts, their fractions and isolated compounds were also included. Where available, the mechanisms of action of the extract or isolated compounds were retrieved. Reviews, newspaper and other non-peer-reviewed articles were excluded. Similarly, studies reporting biological activities of *Z.* species other than those under consideration and in languages other than English were excluded. In this review, a test substance is considered bioactive when the outcome of the substance-treated group was substantial when determined qualitatively or quantitatively compared to controls (untreated group or group that received a standard drug).

The correctness of the scientific/botanical names of the plants reported in the included studies were confirmed with names available in botanical databases, including www.theplantlist.org, https://www.ipni.org/, and https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/, and https://www.tropicos.org. In cases where the plant name in the article was not the acceptable taxonomical nomenclature, the name in the botanical databases was used. A number of reviews have records of plant species in genus *Zanthoxylum*, including *Z. armatum* DC (Brijwal et al., 2013; Mukhtar and Kalsi 2018; Paul et al., 2018; Verma et al., 2021), *Z. limonella* (Supabphol and Tangjitjareonkun 2014), *Z. nitidum* (Roxb.) DC (Lu et al., 2020a), *Z. rhoita* (Roxb.) DC (Madula and Ikpa, 2021), and *Zanthoxylum bungeanum* Maxim (Zhang M. et al., 2017). Some of these reviews are not comprehensive, while others focused on health benefits related to metabolic diseases (Okagu et al., 2021) or the phytoconstituents such as alkaloids (Yuan et al., 2015; Wei et al., 2021), or were published in non-English languages (Zhang M. et al., 2017). In some previous reviews on traditional uses, only selected species were discussed with respect to a particular disease condition, e.g., Imaga (2010) on sickle cell anemia, Ochwang’i et al. (2014) on cancer, Sinan et al. (2019) on malaria, and Obakiro et al. (2020) on tuberculosis. These reviews were carefully analyzed and most of the reviewed studies were excluded from the present review. Hence, this review covers information on the phytochemistry and biological activities of interest for 25 plants species in Genus *Zanthoxylum*, namely *Z. lepreuri* Guill. and Perr., *Z. bungeanum* Maxim. (Syn. *Z. nitidum* Bunge; *Z. piperitum* Benn.; *Z. bungeanum* var. *bungeanum*; *Z. simulans* Hance); *Z. schinifolium* Siebold and Zucc., *Z. clava-herculis* L., *Z. heitzii* (Aubrev. and Pellegr.) P.G.Waterman, *Z. chalybeum* Engl., *Z. allanoides
Z. americanum Mill, Z. armatum DC. (Syn. Z. alatum Roxb.), Z. clava-herculis, Z. epeorn. and Tilter, Z. paracanthum Kowaro, Z. rhetsa DC., Z. buesgenii (Engl.) P.G.Waterman, Z. madagascariensis Baker, Z. astrosinense C.C. Huang, Z. schreberi (J.F.Gmel.) Reynel ex C. Nelson (Syn. Z. monophyllum (Lam.) P. Wilson), Z. rhoifolium Lam., Z. davyi Waterm., Z. ovalifolium Tutcher, Z. fagara (L.) Sarg., Z. tingoassuiba A. St.-Hil., Z. gilletii (De Wild.) P.G.Waterman, and Z. poggei (Engl.) P.G.Waterman.

**Fig. 1** | Proposed mechanism of anticancer activities of natural products from Zanthoxylum species. CAT, catalase; GPx, glutathione peroxidase; COX-2, cyclooxygenase-2; VEGFR-2, vascular endothelial growth factor receptor-2; CDK1, cyclin-dependent kinase-1; ROS, reactive oxygen species; Bax, Bcl-2-associated X protein; APAF-1, apoptosis protein activating factor-1.

**Zanthoxylum Species as Potential Sources of Anticancer Agents**

Cancer is a disease that is characterized by uncontrolled cell division and loss of contact inhibition, leading to formation of tumors. Cancers are resistant to apoptosis and develop angiogenic and metastatic potentials. Prevalence of cancer is rising worldwide, even in developing countries where the rise is partly due to adoption of the Western diet and sedentary lifestyle, and increase in the aging population, among other factors (Moroune et al., 2017). Cancer-related deaths are higher in economically poor countries due to late detection and poor access to treatment and support (India State-Level Disease Burden Initiative Cancer Collaborators, 2018). The number of cancer cases and cancer deaths globally are projected to increase geometrically in the future (Smittenaar et al., 2016), thus placing cancer as a major global health issue. A number of approaches, such as radiation therapies, chemotherapies and surgeries, or their combination, are available for cancer management and treatment. Radiation therapies and surgeries are effective but present cancer patients with discomfort. In most cases, chemotherapies are linked with side effects and some cancers are resistant to chemotherapy. Development of clinically potent cancer drugs that are selectively toxic to cancer cells without harming normal cells has become a public health priority. One promising strategy is to search for natural products with cancer cell-specific cytotoxicity. Some natural compounds from plants and marine organisms have promising applications as anticancer agents (Lichota and Gwozdzinski, 2018). Traditionally, medicinal plants have been used for treating cancer in different parts of the world (Abubakar et al., 2020; Adewole, 2020). Medicinal plants belonging to Z. species and their phytochemicals with anticancer properties are discussed below.

The potential of Z. species in the treatment of cancer has been assessed using both drug-sensitive and drug-resistant cancer cells. For example, antiproliferative activities have been demonstrated using cell culture studies for extracts of Z. clava-herculis L. stem bark against lung cancer (A549) (Wansi et al., 2009), Z. ailanthoides Seibold. and Zucc. stem against human colon cancer cell line (Colo 205) (Chou et al., 2011), Z. heitzii (Aubrév. and Pellegr.) P.G.Waterman fruits and barks against cervical cancer (HeLa), breast cancer (MCF-7), acute monocytic leukemia (THP-1) and human Caucasian prostate cancer (PC-3) (Dzoym et al., 2013), Z. leprieuui and Z. zanthoxyloides fruits against PC-3, MCF-7, liver (WRL-68), and colon (Caco-2) (Misra et al., 2013), Z. rhetsa DC. stem bark and root bark against human stomach-cancer cell lines, SCL, SCL-6, SCL-3706, SCL-9, Kato-3, and NUGC-4 (Ahsan et al., 2014), Z. chalybeum Engl. and Z. paracanthum Kowaro stem bark against drug-sensitive and multidrug-resistant leukemia cell lines (CCRF-CEM and CEM/ADR5000) (Omosa et al., 2019), Z. acanthopodium DC. seed against MCF-7 cell line (Arsita et al., 2019), Z. zanthoxyloides roots against liver cancer (HCC), larynx cancer (HEP2) and breast cancer (BT549) (Andima et al., 2020), and Z. paracanthum root bark against human breast cancer (HCC 1395) and human prostate cancer (DU 145) cell lines (Kaigongi et al., 2020). Most of these reports are inspired by the traditional uses of the plant in managing health conditions, including cancer. Specifically, decoctions of different parts of Zanthoxylum poggei (Engl.) P.G. Waterman are ingested to treat tumors, among other health issues, in Cameroon and Congo (Wouatsa et al., 2013). Using a combination of chromatographic and spectrophotometric techniques, acridone and indoloquinazoline alkaloids, poggeicridone and 2-methoxy-7,8-dehydrotucarpine, respectively were isolated from stem bark of the plant. On exposure to cultured PC-3 cells, the two alkaloids elicited significant cytotoxic effects with IC50 values of 15.8 and 22.1 μM, respectively compared to IC50 value of 0.9 μM for doxorubicin, the reference anticancer drug (Wansi et al., 2016).

These reports have provided support to the traditional uses of decoctions of Z. species alone or as a cocktail with other plant species for managing cancer. Most anticancer natural products act by blocking different mechanisms through which cancer cells grow, multiply and invade other cells, as well as resist the immune system. These mechanisms include the induction of cell cycle arrest, apoptosis and oxidative stress, as well as inhibition of angiogenesis, metastasis and growth signaling pathways in cancer cells (Ahmad et al., 2003; Michalkova et al., 2021). As shown in Fig. 1, extracts of Z. species have been demonstrated to elicit anticancer properties via inhibition of angiogenesis Harahap et al. (2018) and DNA synthesis,
induction of apoptosis Alam et al. (2017) and cell cycle arrest at Go/G1 Pieme et al. (2014) and G2-M phases, and suppression of cyclooxygenase (COX)-2 and vascular endothelial growth factor receptor type-2 (VEGFR-2) expression (Harahap et al., 2018). Table 1 presents the anticancer properties of crude extracts of Z. species whose anticancer constituents are unknown.

Several studies have isolated the Z. species phytochemicals that may be responsible for their in vitro anticancer properties. Based on their classes, chemical compounds derived from Z. species with substantial inhibitory activities against cultured cancer cells are discussed below. An orbitide, [1-8-N

| Extract of Z. species | Range of concentration tested | Cancer model | Pharmacological effects | References |
|------------------------|-------------------------------|--------------|-------------------------|------------|
| Ethanol extract of Z. ailanthoides stem | 31.25–500 μg/ml | Colo 205, Hep G2, B16-F1 and WEHI-3 cells | Suppressed cell viability by 46.4, 18.1, 9.2, and 5.2%, respectively. Extract induced apoptosis and cell cycle arrest at G2/M phase and increased ROS and Ca²⁺ levels, leading to cell damage. Cytotoxic against cancer cells with IC₅₀ value of 48.1 μg/ml. Induced cell cycle arrest at G2/M phase and inhibited angiogenesis via suppression of gene expression of COX-2 and VEGFR-2. | Chou et al. (2011) |
| Ethyl acetate extract of Z. acanthopodium fruits | 31.25–500 μg/ml | 4T1 breast cancer cells | At 200 μg/ml, fruit, bark and leaf extracts inhibited the proliferation of MDA MB-468 by 95, 94.5 and 85.3%, MCF-7 by 79.8, 9.43 and 49.06%, and Caco-2 by 75.8, 61.8 and 68.62%, respectively. Inhibited DNA synthesis and induced apoptosis of the cancer cells. | Harahap et al. (2018) |
| Saponin-rich ethanol extract of Z. armatum DC fruit, bark and leaves | 10–500 μg/ml | Human breast cancer (MDA-MB-468 and MCF-7) and colorectal cancer (Caco-2) cells | Barks showed antiproliferative effects with IC₅₀ values of 66, 76, 8.4, and 42 μg/ml, respectively while the fruit extract was only active against PC-3 and MCF-7 cells with IC₅₀ values of 56 and 26 μg/ml respectively. | Alam et al. (2017) |
| Methanol extracts of fruits and barks of Z. heitzl | 10–100 μg/ml | Human leukemia (HL-60) cells | Cytotoxic against cancer cells with IC₅₀ values of 20 and 12 μg/ml, respectively for fruit and bark extracts. Acted by generating mitochondrial-dependent apoptosis and Go/G1 phase arrest of the cancer cell cycle. | Pie et al. (2014) |
| Methanol extract of Z. heitzl bark and fruits | 1–100 μg/ml | Cervical cancer (HeLa), breast cancer (MCF-7), acute monocytic leukemia (THP-1) and prostate cancer (PC-3) cells | Barks showed antiproliferative effects with IC₅₀ values of 66, 76, 8.4, and 42 μg/ml, respectively while the fruit extract was only active against PC-3 and MCF-7 cells with IC₅₀ values of 56 and 26 μg/ml respectively. | Dzoyem et al. (2015) |
| Methanol extract of Z. leprieuui fruits | 1–100 mg/ml | PC-3, MCF-7, Liver (WRL-68), and colon (Caco-2) cells | Cytotoxic against the cancer cells with IC₅₀ values of 88, >200, 17 and 60 μg/ml respectively relative to doxorubicin with IC₅₀ values of 5.0, 2.1, 0.85 and 3.3 μg/ml, respectively. | Misra et al. (2013) |
| Methanol extract of Z. zanthoxyloides fruits | 1–100 mg/ml | PC-3, MCF-7, WRL-68, and Caco-2 cells | Antiproliferative against the cancer cells with IC₅₀ values of 59, 55, 17 and 66 μg/ml respectively. Cytotoxic against cancer cells with IC₅₀ values of 28.28 and 2.72 μg/ml respectively. | Misra et al. (2013) |
| Dichloromethane/methanol extract of Z. paracanthum root bark | 0.14–100 μg/ml | Human breast cancer (HCC 1395) and human prostate cancer (DU 145) cells | Induced apoptosis and suppression of the expression of genes (p-ERK1/2, MAPK, p-AKT, and c-myc) involved in cancer development and progression (Li et al., 2013). Furthermore, a pyranocoumarin from Z. ailanthoides stem bark, luvangetin exhibited weaker cytotoxic activity against human lung cancer | Kaigongi et al. (2020) |
(A-549) cells with an IC50 value of 4.28 µg/ml compared to 5-fluouracil, a known anticancer agent (IC50 of 0.6 µg/ml) (Cao et al., 2013). Nonetheless, the potential of luvangetin can be further explored by structural modification to possibly obtain more potent anticancer derivatives.

Zanthoxylum-isolated lignans have also been reported to have anticancer activities. Sesamin from Z. parachanthum demonstrated cytotoxic activity against CCRF-CEM and CEM/ADR5000 cancer cells with IC50 values of 40.74 and 30.70 µM, respectively (Omosa et al., 2019). In addition, (-)-xanthoxylol-3,3-dimethylallyl ether from Z. bungeanum Maxim stem bark was cytotoxic against MCF-7 cancer cells with an IC50 of 18.65 µg/ml (Yang et al., 2009) while asarinin from Z. americanum stem suppressed the proliferation of HL-60 cancer cells with IC50 of 11.64 µM (Ju Y et al., 2001). Interestingly, the cytotoxicity of kobusin from Z. rhetsa bark against mouse melanoma (B16-F10) cells was weaker (IC50 values of 112.2 µg/ml) Santhanam et al. (2016) than the activity of kobusin from Z. armatum bark against human lung (A549) and pancreatic (MIA-PaCa) cancer cells (IC50 values of 34.71 and 32.86 µg/ml, respectively) (Mukhija et al., 2014). This demonstrates that activity is dependent on the cancer cell type, possibly because of differences in bioaccessibility of the compounds, their molecular targets and anticancer mechanisms. In general, the lignans acted by inducing apoptosis and cell cycle arrest, and inhibiting DNA synthesis in the cancer cells. In addition to the broad-spectrum antiproliferative properties, the potential of these lignans as anticancer agents is strengthened by the absence of cytotoxicity to human dermal fibroblasts and peripheral blood mononuclear cells.

In many studies, Zanthoxylum alkaloids were reported to exhibit cytotoxic activity against cancer cells in vitro (Wei et al., 2021). Specifically, a furoquinoline alkaloid, skimmianine, demonstrated cytotoxic activity against MCF-7 cancer cells with an IC50 value of 8.03 µg/ml while an aporphine alkaloid, lidirodenine, was cytotoxic against MCF-7, NCI-H460, and SF-268 cancer cells with IC50 values of 3.19, 2.38 and 2.19 µg/ml, respectively (Andima et al., 2020). Recently, acridone alkaloids, fabiocinine and arborinine, and skimmianine from Z. leprieurii Guill. and Perr. root bark were reported to exhibit selective cytotoxicity against HeLa cells with IC50 values of 28.49, 62.71 and 12.8 µg/ml, respectively, which were lower than the activity of anticancer agent, emetine (IC50 values of 0.026 µg/ml against HeLa cells) (Eze et al., 2020). Similarly, an indole alkaloid, canthin-6-one from Z. parachanthum inhibited CCRF-CEM and CEM/ADR5000 cancer cell proliferation with IC50 values of 15.82 and 10.52 µM (Omosa et al., 2019). Unlike doxorubicin, canthin-6-one demonstrated selective cytotoxicity against the drug-resistant cell line without affecting normal human peripheral blood mononuclear cells (Omosa et al., 2019). In other cancer cells (HCC 1395 and DU 145), canthin-6-one and its derivative, 10-methoxycanthin-6-one, from the same plant were strongly cytotoxic with IC50 values of 8.12, and 9.43 µg/ml, and 14.70 and 1.58 µg/ml, respectively (Kaigongi et al., 2020). Despite its lower cytotoxicity against cancer cells compared to doxorubicin, the better selectivity/nontoxicity to normal cells positions canthin-6-one as a promising candidate with a broad-spectrum anticancer activity.

Furthermore, benzophenanthridine alkaloid, 1-methoxy-12,13-dihydro-(1,3) dioxolol (4’,5’,6:4’,5’ benz) (1,2-c) phenanthridine-2,13-diol, from the aerial parts of Z. buesgenii (Engl.) P.G.Waterman showed moderate to strong cytotoxicity against sensitive and multidrug resistant cancer cells (CCRFC-CEM, CEM/ADR5000, MDA-MB231, MDA-MB231/BCRP, HCT116 (p53+/−), HCT116 (p53−/−), U87MG, U87MG.DEGFR, and HepG2) with IC50 values of 0.24, 35.8, 30.14, 65.01, 42.46, 62.34, 60.55, 61.84, and 22.37, respectively, while sparing normal human liver (AML12) cells (Sandjo et al., 2014). Due to the broad-spectrum anticancer activity of the benzophenanthridine and aporphine alkaloids, further studies are required to understand the molecular mechanism of action against the cancer cells. Benzophenanthridine alkaloid from another species (Z. madagascariense Baker), rutaceline, showed inhibitory activity against Caco-2 cells by inducing apoptosis, cell cycle arrest at the G0/G1 phase and DNA fragmentation, and by inhibiting DNA synthesis (Pachón et al., 2007). Acting via similar mechanisms (induction of apoptosis and cell cycle arrest by strong binding to cyclin-dependent kinases (CDK2 and CDK6) and caspases 3 and 8), the ability of a benzophenanthridine alkaloid from Z. zanthoxyloides roots, dihydrochelerythrine to exhibit significant cytotoxicity against HCC and BT549 cancer cells Andima et al. (2020) demonstrates the strong anticancer potential of the benzophenanthridine alkaloids from Z. species. Through unknown mechanisms, other alkaloids such as isoquinoline alkaloids (e.g. nitidine, fagaronine chelerythridine and sanguinarine) from Z. bungeanum elicited selective DNA damage and cytotoxicity against mouse lymphocytic leukemia cells in vitro (Kaminsky et al., 2008; Liao et al., 2013; Tian et al., 2017). Similarly, Z. astrosinense C.C. Huang root-derived carbazole alkaloids, zanthoaustrenines A–C, exhibited strong antiproliferative activities against human leukemia (HL-60), liver (SMMC-7721), lung (A-549), breast (MCF-7) and colon (SW480) cancer cell lines (Fu et al., 2020). Despite the promising in vitro anticancer activities reported, the experimental designs often did not include appropriate positive controls. This is needed for validation of anticancer activities prior to in vivo studies, considering potential differences in assay conditions that may influence cellular activities.

Redox imbalance in cancer cells caused by reduction in antioxidant status and elevation of ROS production and lipid peroxidation has been targeted as a major mechanism through which some plant-derived compounds induce apoptosis (Redzadutordoir and Averill-Bates 2016). Other mechanisms include caspase-mediated signaling, which induces apoptosis, and p53-mediated cell cycle arrest (Zhang Y. et al., 2017). For example, an acridone alkaloid derivative (2-aminoacetamido-10-(3,5-dimethoxy)-benzyl-9(10H)-acridene hydrochloride) was shown to kill leukemia cells by decreasing mitochondrial transmembrane potential while increasing the expression of Bax, cytochrome C and apoptosis protein activating factor-1 to form an apoptosome (Wang et al., 2013). Formation of apoptosome activates caspase-9 with concomitant activation of...
caspase-3, the final inducer of apoptosis. The increase in intracellular ROS production induced by natural products also alters membrane phospholipid composition and integrity, all of which contribute to cancer cell death (Rahman et al., 2021). Taken together, Z. species contain a repertoire of phytochemicals with promising application in the treatment of cancer. However, the reviewed studies were conducted in cell cultures in vitro, without validation of physiological anticancer effects of the extracts or isolated compounds using model organisms or in humans. This is a major limitation of the studies because of pharmacokinetic and pharmacodynamic considerations, which influence the bioaccessibility, bioavailability and target binding/sensitivity of the compounds. Furthermore, some cancer cells have developed mechanisms for resisting the cytotoxic actions of some anticancer agents, such as reduced expression of drug targets while upregulating the

| Compounds | Class of compound | Z. species of source | Cancer cell model | Mechanism of action | Reference |
|-----------|-------------------|---------------------|-------------------|---------------------|-----------|
| [1-8-NaC]-zanriorb A1 | Orbitide | Z. riedelianum leaves | Jurkat leukemia T cells | Induced apoptosis | Beirigo et al. (2016) |
| Chlorogenic acid | Phenolics | Z. ailanthoides stem | Human colon cancers (Colo 205) | Induced apoptosis and cell cycle arrest at the G2/M-phase | Chou et al. (2011) |
| Flavone Isoflavoxin | Alkaloid | Z. chalybeum stem bark | CCRF-CEM and CEM/ADR5000 cancer cells | NR | Li et al. (2013) |
| 4-((soprenoxy)-3-methoxy-3,4-deoxymethylenedioxyfagaramide | Coumarin | Z. schinolkum stem | PG-3, HL-60 and colorectal (SNUGS) cells | Induced apoptosis and suppressed the expression of p-ERK1/2 MAPK, p-AKT, and c-myc genes | Andima et al. (2020) |
| 8-methoxyriinosoumarin H | Coumarin | Z. ailanthoides stem bark | A-549 cells | NR | Cao et al. (2013) |
| Sesamin | Lignan | Z. parachantum stem | CCRF-CEM and CEM/ADR5000 cancer cells | NR | Omosa et al. (2019) |
| (-)-xanthoxylol-3,3-dimethylallyl ether | Lignan | Z. nitidum stem bark | MCF-7 cells | NR | Yang et al. (2009) |
| Asarinin | Lignan | Z. americanum stem | HL-60 cancer cells | NR | Ju Y et al. (2001) |
| Kobusin | Lignan | Z. annatum bark and Z. rhexa bark | mouse melanoma (B16-F10) cells | NR | Santhanam et al., 2016 |
| Smimianine | Alkaloid | Z. bungeanum root | MCF-7 cells | NR | Andima et al. (2020) |
| Liriodenine | Alkaloid | Z. zanthoxylides root | MCF-7, NCI-H460, and SF-268 cancer cells | NR | Andima et al. (2020) |
| 1-methoxy-12-methyl-12,13-dihydro-[1,3]dioxolo[4′,5′,4,5]benzo[1,2-c]phenanthridine-2,13-diol | Alkaloid | Z. buesgenii aerial parts | CCRF-CEM, CEM/ADR5000, MDA-MB231, MDA-MB231/ BCRP, HCT116 (p53kkk), HCT116 (p53kkk), U87MG, U87MGΔEGFR, and HepG2 cells | NR | Sandjo et al. (2014) |
| Rutaceline | Alkaloid | Z. madagascarniense bark | Caco-2 cells | NR | Pachón et al. (2007) |
| Dhydrochelerythrine | Alkaloid | Z. zanthoxylides roots | HCC and BT549 cells | NR | Andima et al. (2020) |
| Nitidine | Alkaloid | Z. bungeanum stem | Mouse lymphocytic leukemia cells | Induced apoptosis and DNA damage | Liao et al., 2013; Tian et al., 2017 |
| Fagaronine | Chelerythrydine | Z. austroasianus root bark | CCRF-CEM, CEM/ADR5000, MCF-7, NCI-H460, and SF-268 cancer cells | NR | Fu et al. (2020) |
| Canthin-6-one | Alkaloid | Z. parachantum bark | CCRF-CEM, CEM/ADR5000, HCC 1995 and DU 145 cells | NR | Omusa et al., 2019; Kaigongi et al., 2020 |
| 10-methoxycanthin-6-one | Alkaloid | Z. parachantum bark | HCC 1995 and DU 145 cells | NR | Kaigongi et al., 2020 |
| hyperoside | flavonol glycoside | Z. bungeanum leaves | Human colorectal cancer cells (SW620) | Induced cell cycle arrest at the G2/M phase and apoptosis | Zhang et al. (2017b) |

NR: Not reported.
expression of alternative survival pathways (Pistritto et al., 2016; Bukowski et al., 2020). Consequently, the multiple target mechanisms of anticancer activities identified in vitro for some Z. species-derived compounds make them strong candidates for in vivo studies and human clinical trials, and further development as anticancer agents. Chemical compounds isolated from Z. species with anticancer properties and their molecular mechanisms are presented in Table 2; Figure 1.

ZANTHOXYLUM SPECIES AS POTENTIAL SOURCES OF ANTIMICROBIAL AGENTS

Microorganisms play many roles essential for human survival and are used as sources of drugs such as antibiotics. However, many strains of bacteria and fungi, such as Streptococcus mutans, S. aureus, Mycobacterium tuberculosis, K. pneumoniae, Candida species, and Escherichia coli are causative agents of many diseases of clinical importance. Several classes of antimicrobial drugs are used to control microbial infections, by suppressing microbial growth or killing them. However, survival pressure has led to the emergence and spread of antibiotics-resistant strains of many microorganisms, including those that are resistant to multiple drugs of the same or different classes (multi-drug resistant strains). These drug resistant strains have led to prolonged treatment duration, frequent hospitalization, increased healthcare cost and mortality from treatable microbial infections (Naylor et al., 2018). This necessitates the urgent search for clinically effective antimicrobial agents against these “superbugs”.

Antimicrobial agents from herbs that are traditionally used in treating microbial infections are being isolated and assessed for activities against drug-resistant microbial strains. Many natural products derived from genus Zanthoxylum show promising antimicrobial activities against bacteria and fungi of public health importance. Investigations for antimicrobial activities are mostly guided by traditional uses of the plant species in the treatment of infectious diseases. Among the Z. species, Z. zanthoxyloides is well known for its use in the management of microbial infections in China and Korea and other parts of Asia as well as in Uganda, Nigeria and Ghana (Anokbonggo et al., 1990; Ngono-Ngane et al., 2000; Imaga 2010; Ynalvez et al., 2012; Ouédraogo et al., 2019; Adeyo et al., 2020). Additionally, Z. zanthoxyloides is used as chewing stick and to treat oral infections and toothaches (Anyawu and Okoye 2017), thus suggesting that the plant species may have antimicrobial activities against oral pathogens. Similarly, Z. rhetsa has been used against urogenital microbial infections and in disinfection of contaminated surfaces in Bangladesh (Yusuf et al., 1994), while Z. lemairei (De Wild) P.G. Waterman is used against malaria and diarrhea (Adesina et al., 1997), Z. chalybeum stem bark against malaria in Rwanda and Ivory Coast (Kamanzi Atindehou et al., 2002), and Z. schreberi (J.F.Gmel.) Reynel ex C. Nelson in treating eye infections in the Caribbean, Venezuela, Colombia and Costa Rica (Rodríguez-Guzmán et al., 2011).

Instead of the whole plant parts, solvent extracts of different parts of Z. species have been investigated for antimicrobial activities. As shown in Table 3, the potency of antimicrobial activity [expressed as minimum inhibitory concentration (MIC) or inhibition zone diameter (IZD)] varies with the different plant species, part used (fruits, leaves, root bark, stem bark), microorganism tested, solvent used for extraction, or type of assay used in the studies. Moderately polar solvents appear to be the best medium for extraction of the antimicrobial compounds compared with highly polar and non-polar solvents (Gonçalves et al., 2019). It is also worth noting that most of the microorganisms studied are drug-sensitive species and only a few studies tested the extracts on drug-resistant microorganisms. Thus, it is challenging to assess and conclude on the potential of individual plant extracts as presented in the literature. It is apparent that the Z. species crude extracts contain antimicrobial principles, which may need to be purified to enhance the activity or for elucidating molecular mechanisms. Nonetheless, the combination of several potentially active principles in the crude extracts may present an opportunity. For instance, aqueous-methanol extract of Z. zanthoxyloides root bark showed antibacterial activity against Streptococcus mutans, Sarcina lutea, and Lactobacillus sp. at IZD of 20, 32, and 56 mm, respectively, at 100 mg/ ml compared to the stronger but limited effect of antibiotic drug, amoxicillin, which was active (IZD of 22 mm at 10 µg/ ml) only against Lactobacillus sp. (Okafor et al., 2017). Multi-component extracts with such promising antimicrobial activity can be further investigated for safety and pharmacological effects as low-cost alternatives to purified compounds or drugs. Aside from solvent extracts, the antimicrobial activities of multi-component essential oils derived from Z. species have been reported (Table 3). In one study, bioautophagy-directed fractionation of essential oil from Z. armatum leaves led to the isolation of β-fenchol and linalool, which had antifungal activities against A. alternata and C. lunata (Guleria et al., 2013).

In general, studies on the Z. species crude extracts and essential oils reported antimicrobial activity as IZD or MIC, and seldom investigated their molecular mechanisms. In one study, n-hexane extract of Z. acanthopodium fruits that was active against M. smegmatis was reported to induce loss of intracellular sodium and potassium ion concentration, suggesting that the extract acted by damaging the bacterial cell wall (Fulistionio et al., 2018). Hong et al. (2017) also reported that essential oil from Z. bungeanum fruits, containing 6,9,12,15-hexadeca-tetraenoic acid-methyl ester, 4-terpinenylacetate, D-limonene, eucalyptol, α-terpineol, β-linalool, δ-cadinene and β-pinene, caused lysis of cultured E. coli membrane. This mechanism was supported by the high amount of bacterial intracellular (nucleic acids and proteins) and cell membrane components in the culture medium. In vivo evaluation in a mouse model of enteritis demonstrated that Z. bungeanum fruit-derived essential oil downregulated the expression of pro-inflammatory cytokines (Hong et al., 2017); this indicates that anti-inflammatory mechanism played a role in host protection by the essential oil against E. coli infection. Indeed, elucidation of molecular mechanisms would be more logical for isolated compounds with defined molecular targets in the microorganisms or host. Nonetheless, knowledge of the molecular basis of antimicrobial effect would enhance the direct utilization of crude extracts of Z. species for pharmacological applications.
TABLE 3 | Summary of the antimicrobial activities of solvent extracts and essential oils from different part of Zanthoxylum species.

| Plant species and part used | Test substance | Microorganism targeted | Activity | References |
|-----------------------------|----------------|------------------------|----------|------------|
| Z. zanthoxyloides fruits    | Crude methanol extract | *P. aeruginosa* | IZD of 15 mm | Misra et al. (2013) |
|                             | Essential oil | *K. pneumonia, P. aeruginosa and S. typhimurium.* | IZD of 12, 11, and 9 mm, resp. | Misra et al. (2013) |
| Z. leprieurii fruits         | Crude methanol extract | *P. aeruginosa* | IZD of 15 mm | Okafor et al. (2017) |
| Z. zanthoxyloides root bark  | Aquaeous-methanol extract | *S. mutans, S. lutea, C. albicans, and A. niger* | IZD of 20–32 mm | Tine et al. (2017) |
| Z. zanthoxyloides root bark  | Essential oil | *S. aureus, E. coli, E. faecalis, and C. albicans* Pan sensitive (H37rv), rifampicin resistant (TMC 331) and isoniazid resistant (TMC 301) strains of *M. tuberculosis* | MIC of 47.3, 75.3 and 125 μg/ml | Bunalema et al. (2017) |
| Z. zanthoxyloides            | Ethylacetate and chloroform extracts | *E. coli, P. aeruginosa, Klebsiella sp, S. pneumoniae and B. cereus* (AS, A. flavus, Trichoderma sp and Candida sp.) | IZD of 7.5–16 mm at 25 mg/ml | Adeeyo et al. (2020) |
| F. heitzii fruits and root bark | Ethanol extract | *E.coli, P. aeruginosa, C. albicans, and A. fumigatis* | MIC of 500 μg/ml (fruit) and 1,000 μg/ml (root; for only A. fumigates) | Dzoyem et al. (2013) |
| Z. clava-herculis leaves and stem bark | Methanol extract | *E. coli (AG102), E. aerogenes (EA27), K. pneumonia (KP63) and Providencia stuartii (NEA16)* | MIC of 64–612 μg/ml | Seukep et al. (2015) |
| Z. bungeanum fruits         | Essential oil | *E. coli* | MIC of 24 mg/ml (cell wall lysis in vitro) | Hong et al. (2017) |
| Z. chalybeum stem bark      | Dichloromethane and ethanol extracts | *S. aureus, S. typhi and P. aeruginosa* | Dichloromethane extract, MIC of 32 μg/ml (*S. aureus*); ethanol extract, MIC values of 32, 250 and 500 μg/ml (*S. aureus*, S. typhi and P. aeruginosa, resp.) | Setiner et al. (2013) |
| Z. chalybeum stem bark      | Dichloromethane, ethylacetate and methanol extracts | Isoniazid-resistant strains of *M. madagascariense* and *M. indicus pranii* | Dichloromethane extract, MIC of 1.25 mg/ml (both); methanol extract, MIC of 1.25 and 2.5 mg/ml, resp. | Chirian et al. (2011) |
| Z. ovalifolium fruit        | Hexane, ethylacetate and methanols extracts | *K. pneumonia* and *S. aureus* | Ethyl acetate extract, IZD of 15 and 16 mm, resp.; n-hexane extract, IZD of 14 and 10 mm, resp.; methanol extract, IZD of 13 and 14 mm, resp. at 100 μg/ml | Pavana and Naka (2020) |
| Z. paracanthum root bark    | Chloroform-ethanol extract | Methicillin-resistant *S. aureus* (MRSA), *E. coli* (ATCC 25922), *S. aureus* (ATCC 25923) and *C. albicans* (ATCC 10231) | MIC of 3.91, 0.98, 1.95 and 7.81 μg/ml, resp. | Kaigongi et al. (2020) |
| Z. bungeanum leaves         | Essential oil | *S. aureus, B. cereus, B. subtilis, L. monocytogenes, S. chal raciaeus, V. parahaemolyticus, A. hydrophila, S. sonnei, V. vulnificus* and *S. enterica* | MIC of 1.25 μg/ml | Lee et al. (2012) |
| Z. tingoassuiba roots       | Methanol and dichloromethane extracts | *S. aureus ATCC 25923 and four multidrug resistant strains of the bacterium* | Methanol extract, IZD of 18.3–23.3; dichloromethane extract, IZD of 13.3–20.3 mm | Costa et al. (2017) |
| Z. armatum leaves           | Crude methanol extract and essential oil | *Attemaria alternata, and Curvularia lunata.* | MIC of 1.071 and 948 μg/ml, resp. | Guleria et al. (2013) |
| Z. leprieurii fruits        | Methanol extract | *S. aureus and S. saprophyticus* | MIC of 2 and 7 μg/ml, resp. | Njoh et al., 2015 |
| Z. acanthopodium fruits     |                  | *M. smegmatis* | MIC value of 64 μg/ml | Julisstono et al. (2018) |
| Z. armatum seeds and fruits | Crude methanol extract | *S. aureus, B. subtilis, E. faecalis, MRSA, and S. epidermidis* | IZD of 11.73–20.72 mm | Phuyal et al. (2020) |

IZD, inhibition zone diameter; MIC, minimum inhibitory concentration.

Efforts have been made to isolate compounds that are responsible for the reported antimicrobial activities of Z. species extracts. Most of the compounds are alkaloids and some possess antimicrobial activity against both drug-sensitive and drug-resistant species of public health importance. For example, alkaloids (6-acetyltyldihydronitidine, 6-acetyltyldihydroavicine and 6-acetyltyldihydrochelerythrine) from the stem bark of *Z. rhoifolium* strongly inhibited the growth of *S. aureus, S. epidermidis, K. pneumonia, S. Setubal,* and *E. coli* with respective MIC values of 1.06, 1.06, 3.12, 3.12, and 1.06 μg/ml (6-acetyltyldihydronitidine), 1.06, 3.12, 1.06, 3.12, and 3.12 μg/ml (6-acetyltyldihydroavicine), and 12.5, 6.25,
6.25, 6.25, and 12.5 μg/ml (6-acetonyldihydrochelerythrine) (Gonzaga et al., 2003). Other antimicrobial alkaloids isolated from Z. species include dihydrochelerythrine from Z. rhetsa roots and stem (Tantapakul et al., 2012); bis-[6-(5,6-dihydrochelerythrinyl)] ether, 6-ethoxy-chelerythrine and 4-methoxy-N-methyl-2-quinolone from Z. schreberi leaves and bark (Rodriguez-Guzmán et al., 2011); β-carboline alkaloids (10-methoxycanthin-6-one and canthin-6-one) and phenantheridine alkaloids (8-acetonyldihydrochelerythrine and 8-oxochelerythrine) from Z. paracanthum root bark (Kaigongi et al., 2020); N-methylcanadine from Z. tingoassuiba A. St.-Hil. roots (Costa et al., 2017); and acridone alkaloids (hydroxy-1,3-dimethoxy-10-methyl-9-acridone and 3-hydroxy-1,5,6-trimethoxy-9-acridone) from Z. leprieurii stem bark (Bunalema et al., 2017). Similar to its broad-spectrum antitumor activity, canthin-6-one was strongly active against several bacteria (S. aureus, E. coli, Proteus vulgaris and Klebsiella aerogenes) and fungi (A. niger and C. albicans), with corresponding MIC values of 0.227, 0.114, 0.114, 0.227, and 0.114 μM, respectively. Furthermore, the acridone alkaloids strongly inhibited first line drug-resistant (H37rv), rifampicin-resistant (TMC 331) and isoniazid-resistant (TMC 301) strains of M. tuberculosis with MIC values of 1.5–8.3 μg/ml (Bunalema et al., 2017), which positions Z. leprieurii as a potential source of antituberculosis agents. Structure-activity relationship studies are needed to identify the pharmacophores of the alkaloids against specific microorganisms or their molecular targets. Likewise, antimicrobial mechanisms of the alkaloids are largely unknown, although Wouatsa et al. (2013) reported that acridone alkaloids, 3-hydroxy-1,5,6-trimethoxy-9-acridone and 2,4'-dihydroxyzanthacridone oxide, from Z. leprieurii fruit extract acted by inhibition of aromatase and glycosyltransferase, which are involved in biosynthesis of bacterial lipopolysaccharides and cell wall.

Apart from alkaloids, other antimicrobial compounds isolated from different Z. species include lignans (e.g., sesamin and syringaresinol) (Rahman et al., 2008), tetraflavanoids (e.g., lemaireones A and B) (Bitchagno et al., 2015), and phytosterols (e.g., stigmasterol) (Kaigongi et al., 2020). Lemaireones A and B from Z. lemairei leaves moderately inhibited multidrug-resistant bacteria, K pneumoniae KP55 and E. coli AG100 with MIC values of 128 mg/ml and 64 mg/ml, respectively against E. coli AG100, and MIC value of 128 mg/ml against K. pneumoniae KP55 (Bitchagno et al., 2015). Furthermore, a polymeric procoyanidin from Z. bungeanum fruit exhibited cytoxicity against drug resistant strains of S. aureus with an MIC value of 128 μg/ml; the compound acted by inhibiting β-lactamase activity and by inducing cell wall damage (Kusuda et al., 2006). This study also showed that the isolated compound has potential for further development as an adjuvant of antibacterial drugs for mitigating the burden of drug-resistant microbial infections. Taken together, it is recommended that future studies should use drug resistant microorganisms since the ultimate goal is to overcome antimicrobial resistance. Findings from the studies reviewed suggest that some of the compounds isolated from Z. species have promising future as source of new antibiotics. Figure 2 shows representative Z. species-derived compounds with anticancer, antiparasitic, antimicrobial or anti-sickling activities.

### ANTIVIRAL POTENTIALS OF ZANTHOXYLUM SPECIES

The emergence and spread of viruses such as SARS-CoV-2, HIV and hepatitis B have led to heightened efforts in search for effective remedies. These efforts include repurposing of drugs developed for other viral diseases as well as exploring for new drug candidates in medicinal plants used in treating viral infections by traditional medicine practitioners. A few studies have reported antiviral activities for extracts from Z. species. Following the folkloric use in treating oral pathogens and symptoms related to picornaviridae infection, Choi (2016) found that the methanol extract of Z. piperitum leaves were cytopotoxic to human rhinoviruses - HRVs (HRV2 and HRV3) and enteroviruses (coxackie A16, B3, and B4 viruses, and human enterovirus71) of picornaviridae virus family with IC50 values of 59, 39, 45, 68, 93, and 4.4 μg/ml, respectively. As the extract had low toxicity against human cells (Hela and Vero cells), the active ingredients, if isolated, can serve as bioactive candidates against viral diseases caused by members of the picornaviridae family. Moreover, leaves of Z. bungeanum are used in Korea and Japan for treating respiratory diseases. To support this use, Ha et al. (2014) reported the anti-influenza virus A/NWS/33 (H1N1) effects of flavonol glycosides, quercetin-3-O-β-D-galactopyranoside, quercetin-3-O-α-L-rhamnopyranoside and kaempferol-3-O-α-L-rhamnopyranoside isolated from the Z. bungeanum leaves; the flavonol glycosides also inhibited influenza A virus neuraminidase activity with IC50 values of 434, 211, and 273 μg/ml, respectively. Influenza A virus neuraminidase is involved in the release of newly made virus particle from infected cells, making it a good target for reducing the spread in host cells. Considering the multiple molecular targets of polyphenols, it is also possible that the antiviral activity was mediated via additional unknown mechanisms.

In addition to influenza virus, the antiviral potentials of Z. species-derived phytochemicals have also been reported against hepatitis B virus. A coumarin, collinin, from chloroform extract of Z. schionifolium bark exhibited anti-hepatitis B virus activity (ED50 of 68.3 μg/ml) and also inhibited HBV-DNA replication (IC50 of 17.1 μg/ml) (Chang et al., 1997). Using a different assay, two alkaloids, 5,6-dihydro-6-methoxynitidine and 5-methoxydictamnine, from Z. bungeanum Maxim roots at 0.2 μM showed higher anti-HBV activities by respectively inhibiting 43.3 and 49.3% of viral multiplication than 10 μM of standard antiviral drug, lamivudine with 29.6% inhibition of standard antiviral drug, lamivudine with 29.6% inhibition (Yang and Chen 2008). In addition, a benzophenanthridine alkaloid (decarine), a furoquinoline alkaloid (γ-fagarine), and an amino alcohol derivative (+)-tembamide) from Z. ailanthoides root bark showed anti-HIV activities (EC50 values <0.05 μg/ml) with no cytotoxicity against normal H9 lymphocyte cells (Cheng et al., 2005). It is challenging to compare the antiviral potential of the Zanthoxylum compounds because of differences in the structural type of
the compounds, target virus, and assay method used in these studies. Nonetheless, due to their selected toxicity to viruses, the Z. species-derived alkaloids warrant further investigation for potential use in treating viral infections.

**ZANTHOXYLUM SPECIES AS POTENTIAL SOURCE OF ANTI-PARASITIC AGENTS**

Human African trypanosomiasis (sleeping sickness), a neglected tropical disease, is a Trypanosoma species-caused parasitic disease that is endemic in sub-Saharan Africa, where majority of the victims are poor rural dwellers. Trypanosoma species is transmitted by tsetse flies and cause a fatal disease if not properly treated. A few T. species, such as T. brucei gambiense, is responsible for the vast majority of Trypanosoma infection in West and Central Africa while T. rhodesiense is mostly responsible for infections in East Africa where less than 10% of the infection exists. The initial (hematolymphatic) stage of infection is asymptomatic and, if detected early, is treatable with pentamidine or suramin while the second (meningoencephalitic) stage, which is characterized by the invasion of the central nervous system by the parasite, is treatable with melarsoprol or eflornithine (Simarro et al., 2011).

Unfortunately, these drugs do not guarantee total recovery as the success rate in most cases is less than 90%. In addition to the growing drug resistance of the parasites, some devastating toxicities accompany the use of these drugs (Shaw et al., 2010). This presents the need for safer and potent alternatives, especially from natural products and medicinal plants that have a history of application in treating the disease. Medicinal plants are used for treating trypanosomiasis in Nigeria (Atawodi et al., 2003; Bulus et al., 2016; Okwor et al., 2020); thus, they have strong prospects for use as sources of clinically relevant anti-trypanosoma agents. In Nigeria and Ghana, roots, stem and leaves of Z. zanthoxyloides are used in treating trypanosomiasis (Mann et al., 2011). When cultured with the root extract, the viability of T. brucei was demonstrated to be suppressed (IC<sub>50</sub> = 3.41 μg/ml) by

![Figure 2](https://www.frontiersin.org/content/12/713090/figure/2)

**FIGURE 2** | Representative bioactive compounds, from different phytochemical classes, isolated from Zanthoxylum species.
induction of apoptosis and cell cycle arrest at G0/G1 phase (Dofuor et al., 2019). Subsequent investigation by the same group resulted in the isolation of an alkaloid, skimmianine, and an oxylipin, 9-oxo-10,12-octadecadienoic acid, from Z. zanthoxyloides root as the cytotoxic principles against T. brucei (GUTat 3.1 strains; EC₅₀ values of 1.7 and 1.2 µM, respectively) (Dofuor et al., 2020). Although less active than diminazene aceturate, an antitrypanosomal drug (EC₅₀ of 0.5 µM), the alkaloids acted by inducing cell cycle arrest at G0-G1 and (G2-M) phases and by inhibiting DNA synthesis of the parasite. Similarly, an acridone alkaloid, arborinine, derived from Z. leprieurii stem bark exhibited antitrypanosomal activity in cultured Trypanosoma brucei (s427) cells with an IC₅₀ of 13.2 µg/ml by unknown mechanisms (Eze et al., 2020). There is a need to test the clinical effectiveness of these isolated compounds in trypanosoma infection to clarify if their in vitro activities can translate into clinically relevant in vivo effects. This is because some therapeutic agents that are active in culture studies are not bioavailable in the gastrointestinal tract or may face transport barriers during transepithelial transport when orally ingested (Udenigwe et al., 2021).

Apart from trypanosomiasis, malaria is another parasitic disease targeted with some Z. species. Malaria is caused by Plasmodium species and is transmitted by Anopheles species through the blood of an infected human. An estimate of over 200 million people die from malaria-related events and a vast majority of these deaths occur in sub-Saharan Africa with Nigeria bearing the highest burden (WHO, 2019). Majority of those who contract and die from malaria are poor rural dwellers who resort to cheap and ineffective drugs that relieve the symptoms, leading to relapses and increase in the development of resistant strains of the parasite (Karunamoorthi et al., 2013). In addition, some individuals are sensitive to some prescription antimalarial drugs (Haakenstad et al., 2019). Consequently, traditional medicine practitioners harness the therapeutic potentials of medicinal plants to treat malaria. Many Zanthoxylum species have been investigated as sources of antimalarial agents. For example, an in vitro study by Mofor et al. (2017) reported that extract of Z. clava-herculis stem bark inhibited multidrug resistant strain of P. species with IC₅₀ of 4.94 µg/ml and with low toxicity against monkey kidney epithelial cell line. Despite the prospects, the phytochemicals responsible for the antimalarial activity and their mechanism of action are unknown. Other studies have attempted to isolate some antimalarial principles from Z. species. Among the compounds, alkaloids, lignans and amides dominated as active compounds. For instance, sesamine from Z. gilletii stem bark showed significant anti-plasmodial activities against chloroquine-sensitive Sierra Leone (D6), chloroquine-resistant Indochina (W2), and artemisinin-resistant strain (3D7) of P. falciparum with IC₅₀ of 1.92, 3.23, and 2.94 µg/ml, respectively (Masinde 2014). Secondary metabolites such as syncarpamide and decarine from Z. syncarpum stem also significantly inhibited both chloroquine-sensitive and chloroquine-resistant strains of malaria parasite; IC₅₀ values of 2.04 and 1.44 µM were recorded against P. falciparum D6 strain and 3.06 and 0.88 µM against P. falciparum W2 strain (Ross et al., 2004). Syncarpamide was cytotoxic against African green monkey kidney (VERO) fibroblast cell line only at high concentration of 56 µM, outside the range of bioactivity concentrations. This suggests that the Z. syncarpum compounds can potentially exhibit anti-plasmodial effect with low toxicity to the host.

Based on the use of different Z. zanthoxyloides parts for treating malaria (Adesina 2005; Enechi et al., 2019), Goodman et al. (2019) that four alkaloids, bis-dihydrochelerythrinyl ether, skimmianine, buesgenine and chelerythrine, isolated from roots, root-bark and stem-bark exhibited anti-plasmodial activity against chloroquine-sensitive (3D7) strains of P. falciparum (IC₅₀ values of 4.3, 0.7, 2.0, and 0.4 µg/ml, respectively). Previous studies on other alkaloids showed that nitidine from Z. gilletii stem bark exhibited anti-plasmodial activity against P. falciparum strain FC51 with IC₅₀ < 5 µg/ml by halting DNA synthesis in the parasite (Zirihi et al., 2005; Zirihi et al., 2009). Moreover, 8-acetonyldihydrochelerythrine from Z. gilletii stem bark inhibited D6, W2, and 3D7 strains of P. falciparum with IC₅₀ values of 4.06, 4.02, and 3.37 µg/ml, respectively through unknown mechanisms (Masinde, 2014). Apart from alkaloids, an amide, fagaramide, isolated from Z. gilletii stem bark was moderately active (IC₅₀ of 7.73, 15.15, and 7.72 µg/ml) against D6, W2, and 3D7 strains of P. falciparum, respectively (Masinde, 2014). Another amide, pellitorine, and a furanoquinolines, γ-fagarine from Z. zanthoxyloides roots, root-bark and stem-bark also inhibited 3D7 strains of P. falciparum with IC₅₀ values of 2.2 and 2.0 µg/ml, respectively (Goodman et al., 2019). It is possible that the anti-plasmodial compounds may have acted alone or together if present in the plant extracts used in treating malaria (Enechi et al., 2019; Amah et al., 2021). Despite the promising results, the mechanism of action of the isolated compounds are unknown and the research design in some cases did not include reference antimalarial agents for comparison. Future studies need to evaluate the clinical efficacy of the isolated anti-plasmodial compounds in susceptible populations as a treatment option for combating resistant species of the malarial parasites.

**POTENTIAL APPLICATION OF ZANTHOXYLUM SPECIES IN SICKLE CELL DISEASE**

Sickle cell disease (SSD) is a group of genetic diseases resulting from inheritance of two abnormal copies of hemoglobin genes. The most common among them is sickle cell anemia. This disease is characterized by hemolytic anemia and occlusion of the blood vessels that reoccurs often. This occlusion is the cause of the excruciating crisis in the joints, a common occurrence in people with SSD. Upon hemolysis, hemoglobin in the erythrocytes is released as free heme (which is pro-inflammatory) and free iron (which by Fenton-type reaction interacts with hydrogen peroxide to form reactive oxygen species). These two components collectively worsen the complications associated with SSD.
Consequently, there has been increased and continuous awareness on the prevention of SSD, and improvement in treatment regimen and other intervention strategies. People who cannot afford anti-sickling drugs like hydroxyurea, nitric oxide, purified poloxamer 118 and piracetam resort to medicinal plants with history of use in subsiding crisis associated with SSD (Okpuzor et al., 2008; Amujoyege et al., 2016). Medicinal plants have been investigated for anti-sickling activities and several have shown promising results. Notably, some members of genus Zanthoxylum (e.g., Z. zanthoxyloides, Z. leprieurii and Z. gilletii) are among the plants with history of traditional use in managing SSD (Akakpo-Akue et al., 2020). Some studies have reported the anti-sickling activities of Z. species and some anti-sickling compounds in these plant species have been isolated and characterized.

Among the species, Z. zanthoxyloides, Z. lemairei, Z. leprieurii, Z. tessmannii and Z. gilletii have been investigated for anti-sickling activity in vitro (Egunyomi et al., 2009; Ouattara et al., 2009). Moreover, the specific compounds responsible for anti-sickling activity of the plant extracts were scarcely reported. Particularly, three divallinoxyquinic acids (burkinabins A, B, and C) isolated from Z. zanthoxyloides root bark at 1.964 mg/ml inhibited sickling of deoxygenated erythrocytes by 77, 78.6 and 82.5% for burkinabins A, B, and C, respectively, which were similar to the effect of sodium chromoglycate, a reference anti-sickling agent (Ouattara et al., 2009). In addition, phenolic acids, such as syringic acid, vanillic acid, proto-catechuic acid, and p-hydroxy-benzoic acid, have been documented to play major roles in the anti-sickling activities of Z. zanthoxyloides (Nurain et al., 2017). However, this conclusion was only based on their identification in high amount in the active plant root extracts. Hence, bioassay-guided fractionation studies are needed to confirm the bioactivity of the phenolic acids, and to isolate other active compounds in the Z. species that showed anti-sickling activities. Generally, the ability of burkinabins A-C to demonstrate good anti-sickling properties has positioned the Z. species as promising sources of therapeutic agents for managing SSD. Clinical trials with the isolated anti-sickling compounds from Z. species are recommended and further studies are needed to modify the compounds to more potent and safer derivatives.

SAFETY OF ZANTHOXYLUM SPECIES

Knowing that not all things natural is safe, there is a need to be cautious in the use of natural products for food and drug. Many natural products have exhibited different levels of toxicity, including lethality at high doses (Al-Nuaimi 2018). For instance, Z. chalybeum root bark extract at 4,000 mg/kg elevated serum creatinine, sodium and potassium levels in rats, as well induced histomorphological deterioration of the intestine in a manner consistent with tumor formation (Engeu et al., 2008). In addition, in vivo and in vitro studies showed that Z. chalybeum leaves, stem bark and root bark (2000 mg/ kg) caused mortality of mice and elicited toxicity against normal human renal epithelium cells. However, after solvent fractionation, no sign of toxicity was recorded at a maximum dose of 5,000 mg/kg, suggesting that the toxic compounds might be acting in synergy. Furthermore, Z. gilletii stem bark applied in treating erectile dysfunction in South Africa and Peru was also reported to elicit histological changes in the reproductive system of male rat after oral administration daily for 14 days. Similarly, at high concentrations, Z. zanthoxyloides stem bark extract was genotoxic and cytotoxic against human leukocytes (Ogunbolude et al., 2014), while Z. leprieurii and Z. zanthoxyloides roots extracts were cytotoxic against normal human prostate epithelium cells (Tandem 2019). Furthermore, Z. zanthoxyloides root bark induced seizure and substantial damage to the liver and kidney, resulting in mortality in mice that received large doses of the herbal materials; LD₅₀ was recorded to be 5 g/kg (Ogwal-Okeng et al., 2003). Z. zanthoxyloides stem bark was also reported to decrease bile release, affecting negatively the serum lipid levels of rats fed the extract (Umaru et al., 2019). In Ugandan folkloric practice, overdose of Z. zanthoxyloides has been recorded to cause short-duration and self-healing stomach disturbances (Anokbonggo et al., 1990). Lastly, Z. heitzii stem bark at doses higher than 6 g/kg elicited toxicity and organ damage in rats (Nchapda et al., 2015). Collectively, toxicities of the Z. species vary based on species, plant part, extraction solvent, dosage, level of phytochemical fractionation, and animal model studied. It is worth noting that the doses of the plant extracts that caused toxicity far exceed those that led to the desirable bioactivity. Nonetheless, caution should be taken to avoid consumption of high doses of the plant preparations to avoid deleterious effects. Furthermore, safe doses of some Z. species are yet to be reported and this information is necessary for traditional medicine practitioners to properly administer the natural products and for the safety of consumers.

CONSERVATION OF ZANTHOXYLUM SPECIES FOR FUTURE APPLICATIONS

Considering the wide use of plants in the genus Zanthoxylum and the risk of extinction, conservationists have been advocating for measures to minimize overexploitation, especially for the species whose roots are the most commonly used part (Mbinile et al., 2020). For example, Ouédraogo et al. (2019) showed that the chemical constituents of the stem bark and root bark of Z. zanthoxyloides are similar; hence, extracts from these parts are likely to have similar biological activities. This observation needs to be confirmed by comparative phytochemics and assessment of biological activities. If the relatedness is established, scientists and traditional practitioners would have sustainable alternatives and thus minimize overharvesting of the plant root. In addition, reforestation of medicinal plants and maintenance of their cell cultures for reuse should be emphasized (Li et al., 2020). Furthermore, genetic modification of medicinal plants to become more resilient to environmental threats, such as drought, will also help to make the species more sustainable.

It is worth noting that the names of some of the plants used in the studies reviewed were the “synonyms” as shown in plant
databases. For example, some studies like Wu et al. (2007) and Fan et al. (2019) reported on Zanthoxylum simulans while Yang and Chen (2008), Yang et al. (2009), Chakthong et al. (2019), Sepsamli and Prihastanti, (2019), Lu et al. (2020a) and Lu et al. (2020b) reported on Zanthoxylum nitidum instead of the accepted nomenclature, “Zanthoxylum bungeanum Maxim”. This issue was noted in several other papers, such as Chrian et al. (2011), Rodriguez-Guzman et al. (2011), Okafor et al. (2017), and Wansi et al. (2009). To address this issue, a recent study applied DNA barcoding for correct identification of plant species that were incorrectly named in previous studies (Veldmana et al., 2020). The authors noted that some medicinal plant researchers do not consult plant taxonomy experts and others do not confirm the plant identity by comparing their features with those available in reputable plant databases. Another possible source of this confusion is the local assignment of arbitrary names to many plant species by herbalists. This could also be associated with intraspecies and interspecies genetic diversity, and variance development because of changes in the environment (Feng et al., 2020). The issue could also be linked to the dependence of researchers in some countries on traditional medicine practitioners to provide and identify therapeutic plants. This system is not reliable. In one instance, some Zanthoxylum species with different chemical constituents and biological activities (Z. bungeanum, Z. schinifolium, and Z. piperitum) were distributed and intermixed as “Zanthoxyl pericarpium” by traditional medicine practitioners in Korea (Jang et al., 2020). Without proper identification, the outcome of research conducted with incorrectly labelled plant samples will be misleading. It is recommended that experts in phytotaxonomy should validate the identity of the plant species prior to further research and development. In addition, molecular characterization of the plant and the use of specific biomarkers may be helpful in ensuring that names given to plants used for phytopharmacological research are credible.

CONCLUSION

Zanthoxylum species are reservoir of phytochemicals with health-promoting properties, such as anti-sickling, antancer and anti-infectious disease activities (Figure 3). The majority of the biological properties reported for Z. species were inspired by their traditional uses as therapeutic agents. Considering that the roots of Z. species are the most sourced parts in trado-medicinal uses, reforestation of the plants is highly recommended to avoid overharvesting. Similarly, the plant culture can be utilized instead of the freshly harvested plants. In many studies, drug-sensitive strains of infectious agents and cancer cells were used to assess bioactivity. Hence, future research should target the activity of Z. species against drug-resistant species or strains. This is important because one of the ultimate goals of new drug development is to curb drug resistance. Furthermore, several Z species phytochemicals with strong bioactivities against infectious microorganisms, especially against drug-resistant strains of malarial parasites, viruses and other microbes, as well as drug-resistant cancer cells should be subjected to clinical trials as potential natural alternatives to synthetic drugs. In addition, since many studies were conducted in vitro, there is a dearth of information on the intestinal transport, bioavailability, bioaccessibility, and bioavailability of many of the active compounds. Additional research is needed to clarify the specific chemical compounds responsible for the promising biological activities of some of the plant extracts as well as the bioactivity and mechanisms of action of some of the isolated compounds. Future research should also confirm bioactivities and safety of the compounds in vivo using animal models and humans. Finally, researchers should endeavor to mimic the traditional methods used in preparation of the plant extract to ensure the preservation of the bioactive principles of interest.

AUTHOR CONTRIBUTIONS

IOU, JCN, and CCU contributed to conception and design of the study. EA conducted the literature search. IOU, JCN, and ECA wrote sections of the first draft of the manuscript. IOU and CCU revised the manuscript. All authors read and approved the submitted version.

REFERENCES

Abubakar, I. B., Ukwuani-Kwaja, A. N., Garba, A. D., Singh, D., Malami, I., Salihu, T. S., et al. (2020). Ethnobotanical Study of Medicinal Plants Used for Cancer Treatment in Kebbi State, North-west Nigeria. Acta Ecologica Sinica 40, 306–314. doi:10.1016/j.chinaes.2020.02.007

Adeeyo, A. O., Odelade, K. A., Msagati, T. A. M., and Odiyo, J. O. (2020). Antimicrobial Potencies of Selected Native African Herbs against Water Microbes. J. King Saud Univ. - Sci. 32, 2349–2357. doi:10.1016/j.jksus.2020.03.013

Adesina, S. K., Olugbade, T. A., Akinwusi, D. D., and Bergenthal, D. (1997). Extractives from Zanthoxylum Lemairei Root and Stem. Pharmazie 52, 720–724.
Adesina, S. (2005). The Nigerian Zanthoxylum: Chemical and Biological Values. Afr. J. Trad. Compl. Alt. Med. 2 (3), 282–301. doi:10.4314/ajtcam.v2i3.31128

Adewole, K. E. (2020). Nigerian Antimalarial Plants and Their Anticancer Potential: A Review. J. Integr. Med. 18, 92–113. doi:10.1007/jjoimj.2020.01.001

Ahmad, M. U., Rahman, M. A., Huq, E., and Chowdhury, R. (2003). Alkaloids of Zanthoxylum Budrunga. Fitoterapia 74, 191–193. doi:10.1016/s0367-326x(02)00286-1

Ahsan, M., Haque, M. R., Hossain, M. B., Islam, S. N., Gray, A. L., and Hasan, C. M. (2014). Cytotoxic Dimeric Quinolone-Terpenic Alkaloids from the Root Bark of Zanthoxylum Rhetsa. Phytochemistry 103, 8–12. doi:10.1016/j.phytochem.2014.03.008

Ahsan, M., Zaman, A. A., Hasan, C. M., Ita, C., and Islam, S. K. (2008). Constituents and Cytotoxicity of Zanthoxylum Bhatia Stem Bark. Fitoterapia 71, 697–700. doi:10.1016/j.fitote.2007.06.014

Al-Nuaimi, A. A. H. D. (2018). Extracts of Plants Used as Traditional Medicines in Nigeria. Proc. Natl. Acad. Sci. 115, 12142–12148. doi:10.1073/pnas.1802606115

Al-Nuaimi, A. A. H. D., Al-Ashouti, M. A. A., and Al-Assaf, S. R. (2017). Antioxidant and Antimicrobial Activities of Thymoquinone and Its Derivatives. J. Integr. Med. 15, 394–401. doi:10.1007/s12539-017-0323-2

Al-Nuaimi, A. A. H. D., Al-Ashouti, M. A. A., and Al-Assaf, S. R. (2018). Antioxidant and Antimicrobial Activities of Thymoquinone and Its Derivatives. J. Integr. Med. 16, 175–184. doi:10.1007/s12539-017-0323-2

Al-Nuaimi, A. A. H. D., Al-Ashouti, M. A. A., and Al-Assaf, S. R. (2019). Antioxidant and Antimicrobial Activities of Thymoquinone and Its Derivatives. J. Integr. Med. 17, 225–236. doi:10.1007/s12539-017-0323-2

Al-Nuaimi, A. A. H. D., Al-Ashouti, M. A. A., and Al-Assaf, S. R. (2020). Antioxidant and Antimicrobial Activities of Thymoquinone and Its Derivatives. J. Integr. Med. 18, 205–216. doi:10.1007/s12539-017-0323-2

Al-Nuaimi, A. A. H. D., Al-Ashouti, M. A. A., and Al-Assaf, S. R. (2021). Antioxidant and Antimicrobial Activities of Thymoquinone and Its Derivatives. J. Integr. Med. 19, 285–294. doi:10.1007/s12539-017-0323-2

Al-Nuaimi, A. A. H. D., Al-Ashouti, M. A. A., and Al-Assaf, S. R. (2022). Antioxidant and Antimicrobial Activities of Thymoquinone and Its Derivatives. J. Integr. Med. 20, 355–366. doi:10.1007/s12539-017-0323-2

Al-Nuaimi, A. A. H. D., Al-Ashouti, M. A. A., and Al-Assaf, S. R. (2023). Antioxidant and Antimicrobial Activities of Thymoquinone and Its Derivatives. J. Integr. Med. 21, 477–488. doi:10.1007/s12539-017-0323-2

Al-Nuaimi, A. A. H. D., Al-Ashouti, M. A. A., and Al-Assaf, S. R. (2024). Antioxidant and Antimicrobial Activities of Thymoquinone and Its Derivatives. J. Integr. Med. 22, 599–610. doi:10.1007/s12539-017-0323-2

Al-Nuaimi, A. A. H. D., Al-Ashouti, M. A. A., and Al-Assaf, S. R. (2025). Antioxidant and Antimicrobial Activities of Thymoquinone and Its Derivatives. J. Integr. Med. 23, 791–802. doi:10.1007/s12539-017-0323-2
Wu, J., Mei, W. L., and Dai, H. F. (2007). A New Monoterpenoid Glycoside from Roots of Zanthoxylum Simulans. Chin. Tradit Herb Drug 38 (4), 488–490. doi:10.1002/chin.200713185

Yang, C. H., Cheng, M. J., Lee, S. J., Yang, C. W., Chang, H. S., and Chen, I. S. (2009). Secondary Metabolites and Cytotoxic Activities from the Stem Bark of Zanthoxylum Nittidum. Chem. Biodivers 6, 846–857. doi:10.1002/cbdv.200800107

Yang, G., and Chen, D. (2008). Alkaloids from the Roots of Zanthoxylum Nittidum and Their Antiviral and Antifungal Effects. Chem. Biodivers 5, 1718–1722. doi:10.1002/cbdv.200890160

Ynalvez, R. A., Cardenas, C., Addo, J. K., Adukpo, G. E., Dadson, B. A., and Addo-Mensa, A. (2012). Evaluation of the Antimicrobial Activity of Zanthoxylum Zanthoxyloides Root Bark Extracts. Res. J. Med. Plant 6 (2), 149–159. doi:10.3923/rjmp.2012.149.159

Yuan, H. M., Qiu, L., Xie, Z. J., Zou, L., Zheng, J., and Fu, Q. (2015). Research Progress on Alkaloids Constituents from Zanthoxylum and Their Pharmacological Activities. Zhongguo Zhong Yao Za Zhi 40 (23), 4573–4584. doi:10.4268/cjcm20152309

Yusuf, M., Chowdhury, J. U., Wahab, M. A., and Begum, J. (1994). Medicinal Plants of Bangladesh. Chittagong, Bangladesh: BCSIR Laboratories.

Zhang, M., Wang, J., Zhu, L., Li, T., Jiang, W., Zhou, J., et al. (2017a). Zanthoxylum Bungeanum Maxim. (Rutaceae): A Systematic Review of its Traditional Uses, Botany, Phytochemistry, Pharmacology, Pharmacokinetics, and Toxicology. Int. J. Mol. Sci. 18 (10), 2172. doi:10.3390/ijms18102172

Zhang, Y., Dong, H., Zhang, J., and Zhang, L. (2017b). Inhibitory Effect of Hyperoside Isolated from Zanthoxylum Bungeanum Leaves on SW620 Human Colorectal Cancer Cells via Induction of the P53 Signaling Pathway and Apoptosis. Mol. Med. Rep. 16 (2), 1125–1132. doi:10.3892/mmr.2017.6710

Zirihi, G. N., Mambu, L., Guédé-Guina, F., Bodo, B., and Grellier, P. (2005). In Vitro Anti-Plasmodial Activity and Cytotoxicity of 33 West African Plants Used for Treatment of Malaria. J. Ethnopharmacol 98, 281–285. doi:10.1016/j.jep.2005.01.004

Zirihi, G. N., Ngueslan, K., Eiten, D. T., and Serikouassi, B. P. H. (2009). Evaluation In Vitro of Anti-Plasmodial Activity of Ethanolic Extracts of Funetia Elastica, Rauvolfia Vomitoria and Zanthoxylum Gilletii on Plasmodium Falciparum Isolates from Côte d’Ivoire. J. Anim. Plant Sci. 5 (1), 406–413.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.